Jacinda Beth Sampson, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sampson’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C135776 · Current
Licensed to practise in California · since 2015 · expires 2027-04-30 · University of Alabama School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$18,755
Medicare paid this office $18,755 for 118 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 49 | $6,495 | $116 |
| Long return visit (40+ min) | 24 | $4,514 | $150 |
| Return visit (30+ min) | 16 | $1,497 | $79 |
| Return visit (30+ min) | 11 | $1,239 | $113 |
Who their Medicare patients are
118 Original Medicare patients in 2024. Average age 68 · Women 51% · Also on Medicaid 22% · Health risk score 1.64. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 67% · Depression 31% · Coronary heart disease 26% · Diabetes 23% · Cancer 17% · Atrial fibrillation 17% · Chronic kidney disease 14% · Stroke 14% · Heart failure 13% · Dementia 10%.
The office billed $70,941, Medicare allowed $26,094 and paid $18,755; for 184 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 118 | 184 | 68 | 1.64 | $70,941 | $18,755 |
| 2023 | 120 | 184 | 69 | 1.55 | $66,225 | $20,015 |
| 2022 | 153 | 229 | 65 | 1.52 | $98,897 | $26,120 |
| 2021 | 142 | 263 | 68 | 1.71 | $104,888 | $30,294 |
| 2020 | 174 | 289 | 68 | 1.75 | $102,055 | $27,137 |
| 2019 | 154 | 268 | 67 | 1.59 | $41,588 | $26,729 |
| 2018 | 140 | 259 | 67 | 1.70 | $33,433 | $22,310 |
| 2017 | 135 | 267 | 68 | 1.64 | $61,346 | $23,601 |
| 2016 | 138 | 250 | 70 | 1.56 | $73,389 | $23,906 |
| 2015 | 87 | 164 | 68 | 1.84 | $59,791 | $13,606 |
| 2014 | 112 | 379 | 67 | 1.65 | $142,052 | $29,828 |
| 2013 | 111 | 362 | 66 | 1.77 | $114,335 | $34,433 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 74 | $11,851 | $123 |
| New patient visit (60+ min) | 23 | $3,583 | $156 |
| Return visit (30+ min) | 29 | $2,857 | $79 |
2022: 3 services
| Long return visit (40+ min) | 103 | $16,478 | $119 |
| New patient visit (60+ min) | 31 | $5,048 | $163 |
| Return visit (30+ min) | 23 | $2,456 | $85 |
2021: 4 services
| Long return visit (40+ min) | 98 | $19,334 | $130 |
| Return visit (30+ min) | 37 | $4,461 | $84 |
| New patient visit (60+ min) | 26 | $4,399 | $169 |
| Short return visit (20+ min) | 11 | $628 | $57 |
2020: 4 services
| Long return visit (40+ min) | 82 | $11,803 | $100 |
| New patient visit (60+ min) | 48 | $7,161 | $149 |
| Return visit (30+ min) | 56 | $4,297 | $69 |
| Short return visit (20+ min) | 13 | $622 | $48 |
2019: 3 services
| Long return visit (40+ min) | 105 | $15,893 | $98 |
| New patient visit (60+ min) | 42 | $6,385 | $152 |
| Return visit (30+ min) | 40 | $3,445 | $69 |
2018: 6 services
| Long return visit (40+ min) | 53 | $7,007 | $95 |
| Return visit (30+ min) | 56 | $4,390 | $66 |
| Long return visit (40+ min) | 34 | $3,591 | $100 |
| New patient visit (60+ min) | 21 | $2,712 | $129 |
| Return visit (30+ min) | 26 | $1,837 | $71 |
| Short return visit (20+ min) | 11 | $415 | $38 |
2017: 4 services
| Long return visit (40+ min) | 62 | $8,821 | $95 |
| Return visit (30+ min) | 74 | $7,129 | $68 |
| New patient visit (60+ min) | 37 | $5,222 | $141 |
| New patient visit (45+ min) | 15 | $1,462 | $97 |
2016: 5 services
| New patient visit (60+ min) | 47 | $7,134 | $152 |
| Return visit (30+ min) | 54 | $5,870 | $72 |
| New patient visit (45+ min) | 42 | $4,761 | $113 |
| Long return visit (40+ min) | 33 | $4,570 | $99 |
| Short return visit (20+ min) | 28 | $1,413 | $47 |
2015: 7 services
| Long return visit (40+ min) | 37 | $4,274 | $110 |
| New patient visit (60+ min) | 14 | $2,104 | $150 |
| New patient visit (45+ min) | 12 | $1,389 | $116 |
| Test to measure expiratory airflow and volume | 34 | $1,161 | $33 |
| Evaluation of speech sound production | 14 | $1,138 | $81 |
| Return visit (30+ min) | 12 | $1,038 | $87 |
| Evaluation of swallowing function | 11 | $823 | $75 |
2014: 5 services
| Long return visit (40+ min) | 90 | $13,994 | $111 |
| Evaluation of speech sound production | 45 | $4,568 | $79 |
| Evaluation of swallowing function | 41 | $3,915 | $75 |
| Test to measure expiratory airflow and volume | 72 | $3,142 | $32 |
| Return visit (30+ min) | 15 | $1,420 | $95 |
2013: 5 services
| Long return visit (40+ min) | 87 | $14,482 | $120 |
| Evaluation of speech, language, voice, communication, or hearing processing | 46 | $10,532 | $191 |
| Evaluation of swallowing function | 38 | $3,109 | $68 |
| Test to measure expiratory airflow and volume | 70 | $3,086 | $32 |
| Return visit (30+ min) | 12 | $1,370 | $91 |
Medicaid work
$793 in 2023
Medicaid paid $793 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 12 | $793 |
| 2023 | 12 | 1 | 12 | $793 |
Drugs they prescribed that Part D paid
$1,074,470
Pharmacies billed $1,074,470 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
294 generic and 75 brand-name prescriptions · $1,074,470 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Radicava Ors | 57 | $771,930 | $13,543 |
| Riluzole | 40 | $5,191 | $130 |
| Atovaquone | 16 | $1,797 | $112 |
| Baclofen | 33 | $1,417 | $43 |
| Pyridostigmine | 12 | $1,055 | $88 |
See all 10 drugs
| Radicava Ors | 57 | $771,930 | $13,543 |
| Riluzole | 40 | $5,191 | $130 |
| Atovaquone | 16 | $1,797 | $112 |
| Baclofen | 33 | $1,417 | $43 |
| Pyridostigmine | 12 | $1,055 | $88 |
| Carbidopa-Levodopa | 27 | $784 | $29 |
| Gabapentin | 30 | $748 | $25 |
| Carbidopa-Levodopa Er | 25 | $454 | $18 |
| Tizanidine | 11 | $268 | $24 |
| Prednisone | 15 | $137 | $9 |
Year by year
| 2024 | 369 | 57 | None | 20% | $1,074,470 |
| 2023 | 396 | 68 | 0% (0) | None | $1,472,274 |
| 2022 | 357 | 52 | None | 22% | $1,093,106 |
| 2021 | 350 | 47 | None | 17% | $598,039 |
| 2020 | 251 | 41 | 0% (0) | 15% | $194,114 |
| 2019 | 328 | 59 | None | 20% | $257,347 |
| 2018 | 483 | 66 | None | 31% | $702,132 |
| 2017 | 327 | 57 | None | 15% | $110,112 |
| 2016 | 324 | 67 | None | 8% | $166,171 |
| 2015 | 389 | 55 | None | 21% | $72,285 |
| 2014 | 305 | 65 | None | None | $135,304 |
| 2013 | 188 | 56 | None | None | $83,592 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Evrysdi | 28 | $717,524 | $25,626 |
| Radicava Ors | 28 | $394,332 | $14,083 |
| Relyvrio | 13 | $166,073 | $12,775 |
| Atovaquone | 15 | $13,573 | $905 |
| Riluzole | 28 | $6,764 | $242 |
| Gabapentin | 58 | $1,347 | $23 |
| Baclofen | 43 | $1,319 | $31 |
| Carbidopa-Levodopa | 31 | $677 | $22 |
| Carbidopa-Levodopa Er | 19 | $550 | $29 |
| Prednisone | 13 | $410 | $32 |
| Duloxetine | 21 | $373 | $18 |
| Tizanidine | 11 | $313 | $28 |
| Pregabalin | 17 | $225 | $13 |
2022: 11 drugs
| Evrysdi | 32 | $786,376 | $24,574 |
| Radicava | 21 | $274,502 | $13,072 |
| Riluzole | 21 | $2,884 | $137 |
| Gabapentin | 62 | $1,716 | $28 |
| Carbidopa-Levodopa Er | 14 | $1,607 | $115 |
| Baclofen | 35 | $1,542 | $44 |
| Atropine Sulfate | 20 | $1,454 | $73 |
| Pyridostigmine | 13 | $865 | $67 |
| Duloxetine | 20 | $331 | $17 |
| Carbidopa-Levodopa | 14 | $185 | $13 |
| Amitriptyline | 11 | $106 | $10 |
2021: 10 drugs
| Evrysdi | 13 | $297,692 | $22,899 |
| Radicava | 21 | $259,066 | $12,336 |
| Nuedexta | 19 | $28,908 | $1,521 |
| Riluzole | 49 | $4,313 | $88 |
| Pyridostigmine | 14 | $1,658 | $118 |
| Gabapentin | 53 | $1,129 | $21 |
| Carbidopa-Levodopa Er | 16 | $929 | $58 |
| Duloxetine | 23 | $454 | $20 |
| Carbidopa-Levodopa | 25 | $329 | $13 |
| Amitriptyline | 11 | $122 | $11 |
2020: 7 drugs
| Radicava | 13 | $149,362 | $11,489 |
| Nuedexta | 24 | $30,140 | $1,256 |
| Riluzole | 35 | $5,744 | $164 |
| Pregabalin | 14 | $925 | $66 |
| Carbidopa-Levodopa | 22 | $588 | $27 |
| Donepezil | 11 | $222 | $20 |
| Gabapentin | 20 | $216 | $11 |
2019: 7 drugs
| Radicava | 17 | $184,999 | $10,882 |
| Nuedexta | 17 | $26,573 | $1,563 |
| Riluzole | 60 | $17,149 | $286 |
| Lyrica | 15 | $8,603 | $574 |
| Gabapentin | 46 | $881 | $19 |
| Carbidopa-Levodopa | 13 | $252 | $19 |
| Prednisone | 11 | $65 | $6 |
2018: 14 drugs
| Radicava | 54 | $615,822 | $11,404 |
| Nuedexta | 40 | $40,857 | $1,021 |
| Riluzole | 69 | $18,185 | $264 |
| Lyrica | 22 | $11,278 | $513 |
| Pyridostigmine Bromide Er | 11 | $1,771 | $161 |
| Gabapentin | 46 | $1,268 | $28 |
| Acetazolamide | 11 | $1,167 | $106 |
| Duloxetine | 22 | $1,058 | $48 |
| Pyridostigmine | 12 | $676 | $56 |
| Methotrexate | 19 | $619 | $33 |
| Celecoxib | 15 | $592 | $39 |
| Prednisone | 20 | $154 | $8 |
| Baclofen | 13 | $140 | $11 |
| Trazodone | 24 | $89 | $4 |
2017: 11 drugs
| Riluzole | 37 | $10,956 | $296 |
| Lyrica | 22 | $9,975 | $453 |
| Pyridostigmine Bromide Er | 12 | $7,891 | $658 |
| Pyridostigmine | 17 | $1,274 | $75 |
| Duloxetine | 21 | $1,064 | $51 |
| Azathioprine | 14 | $748 | $53 |
| Gabapentin | 41 | $592 | $14 |
| Methotrexate | 11 | $542 | $49 |
| Baclofen | 20 | $291 | $15 |
| Prednisone | 14 | $184 | $13 |
| Trazodone | 21 | $78 | $4 |
2016: 10 drugs
| Privigen | Immune globulin | 11 | $153,077 | $13,916 |
| Gabapentin | None | 42 | $1,377 | $33 |
| Duloxetine | None | 22 | $1,202 | $55 |
| Azathioprine | None | 18 | $657 | $37 |
| Baclofen | None | 13 | $270 | $21 |
| Prednisone | None | 29 | $239 | $8 |
| Carbidopa-Levodopa | None | 12 | $219 | $18 |
| Amitriptyline | None | 15 | $198 | $13 |
| Pyridostigmine | None | 15 | $177 | $12 |
| Donepezil | None | 14 | $78 | $6 |
2015: 11 drugs
| Nuedexta | 44 | $32,990 | $750 |
| Riluzole | 55 | $15,967 | $290 |
| Baclofen | 57 | $2,519 | $44 |
| Divalproex Sodium Er | 12 | $2,212 | $184 |
| Glycopyrrolate | 19 | $1,537 | $81 |
| Tizanidine | 28 | $1,318 | $47 |
| Dantrolene | 17 | $1,164 | $68 |
| Gabapentin | 11 | $222 | $20 |
| Amitriptyline | 11 | $143 | $13 |
| Escitalopram | 25 | $134 | $5 |
| Trazodone | 21 | $98 | $5 |
2014: 6 drugs
| Nuedexta | 35 | $28,173 | $805 |
| Riluzole | 31 | $17,605 | $568 |
| Glycopyrrolate | 19 | $1,483 | $78 |
| Baclofen | 36 | $1,365 | $38 |
| Gabapentin | 21 | $523 | $25 |
| Trazodone | 13 | $184 | $14 |
2013: 4 drugs
| Rilutek | 16 | $46,830 | $2,927 |
| Albuterol Sulfate | 12 | $2,473 | $206 |
| Gabapentin | 15 | $1,330 | $89 |
| Baclofen | 13 | $251 | $19 |
Money from drug and device companies
$473 in 2025
| 2025 | 2 | 2 | $458 | $473 |
| 2024 | 1 | 1 | None | $92 |
| 2023 | 3 | 4 | $2,759 | $2,960 |
| 2022 | 1 | 1 | None | $121 |
| 2021 | 1 | 1 | None | $65 |
| 2020 | 1 | 2 | $60 | $60 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Vertex Pharmaceuticals | None | $458 | 1 payment
|
| Ucb | Rystiggo | $15 | 1 payment
|
See all 2 published payments
| Vertex Pharmaceuticals | Consulting · 2025-11-25 | None | $458 |
| Ucb | Education · 2025-06-03 | Rystiggo | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $92
| Novartis Pharmaceuticals | Zolgensma | $92 | 1 payment
|
2023: $2,960
| Biogen | Spinraza | $2,802 | 2 payments
|
| Genentech | Evrysdi | $141 | 1 payment
|
| Novartis Gene Therapies Inc. (fka AveXis Inc.) | Zolgensma | $18 | 1 payment
|
2022: $121
| Biogen | None | $121 | 1 payment
|
2021: $65
| Novartis Gene Therapies Inc. (fka AveXis Inc.) | Zolgensma | $65 | 1 payment
|
2020: $60
| Novartis Gene Therapies Inc. (fka AveXis Inc.) | None | $60 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ionis Pharmaceuticals, Inc. · A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered Ion373 in Patients With Alexander Disease · 2025 | Their institution | $122,871 |
| Genentech, Inc. · Gen Extend · 2021 | Their institution | $116,827 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1/2, Randomized, Double-Blind, Placebo?Controlled Single- and Multiple?Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vx?670 in Adult Subjects With Myotonic Dystrophy Type 1 · 2025 | Their institution | $76,603 |
| Genentech, Inc. · Gen Extend · 2020 | Their institution | $32,977 |
| PFIZER INC. · Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 Enddm1 · 2025 | Their institution | $12,666 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1/2, Randomized, Double-Blind, Placebo‑Controlled Single- and Multiple‑Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vx‑670 in Adult Subjects With Myotonic Dystrophy Type 1 · 2024 | Their institution | $8,782 |
| VERTEX PHARMACEUTICALS INCORPORATED · Study of Vx-670 in Adult Participants With Myotonic Dystrophy 1 (Dm1) · 2023 | Their institution | $2,810 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1427000710
- Licence
- CA C135776California C135776: Current · expires 2027-04-30
- Trained
- University of Alabama School of Medicine, 2000
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0008X (2084N0008X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-05-16
- NPI last updated
- 2024-12-10
- NPI record certified
- 2024-12-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 725 Welch Rd, Palo Alto, CA, 94304